Report - Financial Results of Astellas for Fiscal Year 2013 (IFRS) · co-promotion of XTANDI in the US. - Research and development (R&D) expenses were ¥191.5 billion, up 20.3% year-on-year,

Select PornographicDefamatoryIllegal/UnlawfulSpamOther Terms Of Service ViolationFile a copyright complaint

Please pass captcha verification before submit form